The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin
Abstract
Recent studies have indicated that promoting ferroptosis is a promising approach to attenuate drug resistance of cancer cells. Hence, this study aimed to induce ferroptosis in osteosarcoma cells, thereby increasing the sensitivity to cisplatin. Osteosarcoma cells MG63 and Saos‐2 were incubated with increasing doses of cisplatin to generate cisplatin‐resistant strains, MG63/DDP and Saos‐2/DDP. 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) and flow cytometry assays were performed to evaluate cell proliferation and cell death, respectively. Malondialdehyde (MDA), reactive oxygen species (ROS), and lipid oxidation in cells were measured to evaluate the degree of cell ferroptosis. MG63/DDP and Saos‐2/DDP cells showed increased viability and decreased death rate compared with MG63 and Saos‐2 cells, respectively, upon cisplatin treatment. Western blotting analysis indicated that protein levels of p‐STAT3 (Ser727), nuclear factor erythroid 2‐related factor 2 (Nrf2), and glutathione peroxidase 4 (GPx4) in drug‐resistant strains increased significantly in response to cisplatin. Co‐treatment with cisplatin and agonists of ferroptosis, Erastin, and RSL3, remarkably increased MDA, ROS, lipid oxidation, and sensitivity to cisplatin, in MG63/DDP and Saos‐2/DDP cells. Similar results were observed by co‐treatment of cells with cisplatin and a STAT3 inhibitor. The reduction of protein levels of p‐STAT3 (Ser727), Nrf2, and GPx4 in MG63/DDP and Saos‐2/DDP cells resulted in increased ferroptosis and sensitivity to cisplatin. These results indicate that cisplatin‐resistant osteosarcoma cells inhibited ferroptosis after exposure to low doses of cisplatin. However, ferroptosis agonists and STAT3 inhibitor reactivated ferroptosis in the cells and consequently increased sensitivity to cisplatin. This study demonstrates a new approach to attenuate resistance of osteosarcoma to cisplatin in vitro .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
CHEN, L., LI, X., LIU, L., YU, B., XUE, Y., & LIU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.3712 · Cited by 279
RetractedFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Glutaminolysis and transferrin regulate ferroptosis
Gao, M., Monian, P., Quadri, N., Ramasamy, R., & Jiang, X. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.011 · Cited by 2,069
Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis
Ingold, I., Berndt, C., Schmitt, S., Doll, S., Poschmann, G., Buday, K., Roveri, A., Peng, X., Porto Freitas, F., Seibt, T., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.048 · Cited by 1,656
Cao, J. Y., & Dixon, S. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2194-1 · Cited by 1,515
Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, D. C., Weinberg, J. M., Linkermann, A., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411006a · Cited by 1,146 · cited 2×
“There are studies showing that administration of erastin and RSL3, which are ferroptosis agonists, increased cell death in cancers, such as fibrosarcoma (Skouta et al., 2014), lung cancer (Cao and Dixon, 2016), and renal carcinoma (Gao et al., 2015).”
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,040
Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells
Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., & Brady, N. R. (2015) · Oncoscience · doi:10.18632/oncoscience.160 · Cited by 524
Sato, M., Kusumi, R., Hamashima, S., Kobayashi, S., Sasaki, S., Komiyama, Y., Izumikawa, T., Conrad, M., Bannai, S., & Sato, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-19213-4 · Cited by 403
Weir, N. M., Selvendiran, K., Kutala, V. K., Tong, L., Vishwanath, S., Rajaram, M., Tridandapani, S., Anant, S., & Kuppusamy, P. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.2.3577 · Cited by 275
Ferroptosis is a lysosomal cell death process
Gao, H., Bai, Y., Jia, Y., Zhao, Y., Kang, R., Tang, D., & Dai, E. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.078 · Cited by 244
Ma, S., Dielschneider, R. F., Henson, E. S., Xiao, W., Choquette, T. R., Blankstein, A. R., Chen, Y., & Gibson, S. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182921 · Cited by 203
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Rudin, C. M., Yang, Z., Schumaker, L. M., VanderWeele, D. J., Newkirk, K. A., Egorin, M. J., Zuhowski, E. G., & Cullen, K. J. (2003) · PubMed · Cited by 174
Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma
Ara, T., Nakata, R., Sheard, M. A., Shimada, H., Buettner, R., Groshen, S. G., Ji, L., Yu, H., Jove, R., Seeger, R. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2353 · Cited by 134
Yamaguchi, H., Hsu, J. L., Chen, C., Wang, Y., Hsu, M., Chang, S.-S., Du, Y., Ko, H., Herbst, R. S., & Hung, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2621 · Cited by 133
Fetoni, A. R., Paciello, F., Mezzogori, D., Rolesi, R., Eramo, S. L. M., Paludetti, G., & Troiani, D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.359 · Cited by 116
Prognostic factors and survival rate of osteosarcoma: A single‐institution study
Ismail, W. F. N. B. W., Saad, A. Z. M., Alsaigh, L. N., Azman, M. Z. N., Musa, K. I., Biswal, B. M., Bhavaraju, V. M. K., SALZIHAN, M. S., Hasnan, J., Ezane, A. M., et al. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12346 · Cited by 107
Sun, C., Zhu, Y., Li, X., Wang, X., Tang, L., Su, Z., Li, C., Zheng, G., & Feng, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00092 · Cited by 88
Li, G., Zhao, L., Li, W., Fan, K., Qian, W., Hou, S., Wang, H., Dai, J., Wei, H., & Guo, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2135 · Cited by 82
Bouralexis, S., Findlay, D. M., Atkins, G. J., Labrinidis, A., Hay, S. J., & Evdokiou, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601021 · Cited by 70
Yu, W., Tang, L., Lin, F., Yao, Y., Shen, Z., & Zhou, X. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.10.001 · Cited by 45
Gao, S., Zhan, L., Yang, Z., Shi, R., Li, H., Xia, Z., Yuan, S., Wu, Q., Wang, T., & Yao, S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000481755 · Cited by 42
Huang, J. X., Liu, K., Song, D., Ding, M., Wang, J., Jin, Q., & Ni, J. (2015) · Cancer Science · doi:10.1111/cas.12864 · Cited by 35
Liu, Y., Xu, Y., Lin, N., JIANG, S.-J., Wang, Y., & Ye, Z. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0314-9 · Cited by 15
Cited by
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Xu, C., Sun, S., Johnson, T., Qi, R., Zhang, S., Zhang, J., & Yang, K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109235 · Cited by 518
Ouyang, S., Li, H., Lou, L., Huang, Q., Zhang, Z., Mo, J., Li, M., Lu, J., Zhu, K., Chu, Y., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102317 · Cited by 507
The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis
Santana-Codina, N., Gikandi, A., & Mancias, J. D. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-62026-4_4 · Cited by 301
Fu, D., Wang, C., Yu, L., & Yu, R. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00271-y · Cited by 283
Metadata
- Authors
- Liu, Q., & Wang, K.
- Venue
- Cell Biology International
- Publisher
- Wiley
- Published
- 2019-07-18
- Volume
- 43
- Issue
- 11
- Pages
- 1245-1256
- ISSN
- 1065-6995 (ISSN-L)
- 1095-8355
- OpenAlex
- W2915657188
- Cited by
- 271
- References
- 25
- FWCI
- 17.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.